Thiazolidinediones and risk of heart failure in patients with or at high risk of type 2 diabetes mellitus: A meta-analysis and meta-regression analysis of placebo-controlled randomized clinical trials

American Journal of Cardiovascular Drugs

Volumn 11, Issue 2, 2011, Pages 115-128

  Hernandez, Adrian V ^a   Usmani, Ali ^a   Rajamanickam, Anitha ^a   Moheet, A ^b  

^a LERNER RESEARCH INSTITUTE   (United States)

^b ROCHESTER GENERAL HOSPITAL   (United States)

Author keywords

Glucose intolerance, treatment; Heart failure, drug induced; Insulin resistance, treatment; Meta analysis; Metabolic syndrome, treatment; Oedema, drug induced; Pioglitazone, adverse reactions; Rosiglitazone, adverse reactions; Thiazolidinediones, adverse reactions; Type 2 diabetes mellitus, treatment

Indexed keywords

2,4 THIAZOLIDINEDIONE DERIVATIVE; PIOGLITAZONE; ROSIGLITAZONE;

ADULT; AGED; ARTICLE; CARDIOVASCULAR RISK; CLINICAL EVALUATION; DATA EXTRACTION; DISEASE ASSOCIATION; DRUG EFFECT; FEMALE; HEART FAILURE; HUMAN; MALE; MEDLINE; META ANALYSIS; NON INSULIN DEPENDENT DIABETES MELLITUS; PERIPHERAL EDEMA; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL (TOPIC); RISK; SYSTEMATIC REVIEW;

DIABETES MELLITUS, TYPE 2; HEART FAILURE; HUMANS; RANDOMIZED CONTROLLED TRIALS AS TOPIC; REGRESSION ANALYSIS; RISK FACTORS; THIAZOLIDINEDIONES;

EID: 79953236112     PISSN: 11753277     EISSN: 1179187X     Source Type: Journal    
DOI: 10.2165/11587580-000000000-00000     Document Type: Article

References (73)

1. Selvin E, Bolen S, Yeh HC, et al. Cardiovascular outcomes in trials of oral diabetes medications: A systematic review. Arch InternMed 2008; 168: 2070-80
2. Nissen SE, Wolski K. Effect of rosiglitazone on the risk of myocardial infarction and death fromcardiovascular causes.N Engl JMed 2007; 356: 2457-71 (Pubitemid 46919772)
3. Lincoff AM, Wolski K, Nicholls SJ, et al. Pioglitazone and risk of cardiovascular events in patients with type 2 diabetes mellitus: A meta-analysis of randomized trials. JAMA 2007; 298: 1180-8 (Pubitemid 47403104)
4. Singh S, Loke TK, Furberg CD. Long-term risk of cardiovascular events with rosiglitazone: A meta-analysis. JAMA 2007; 298: 1189-95 (Pubitemid 47403105)
5. Lago RM, Singh PP, Nesto RW. Congestive heart failure and cardiovascular death in patients with pre-diabetes and type 2 diabetes given thiazolidinediones: A meta-analysis of randomized clinical trials. Lancet 2007; 370: 1129-36 (Pubitemid 47464583)
6. Berlie HD, Kalus JS, Jaber LA. Thiazolidinediones and the risk of edema: A meta-analysis. Diabetes Res Clin Pract 2007; 76: 279-89 (Pubitemid 46400130)
7. Karalliedde J, Buckingham RE. Thiazolidinediones and their fluid-related adverse effects: Facts, fiction and putative management strategies. Drug Saf 2007; 30: 741-53 (Pubitemid 47347350)
8. Buckingham RE, HannaA. Thiazolidinedione insulin sensitizers and the heart: A tale of two organs? Diabetes Obes Metab 2008; 10: 312-28 (Pubitemid 351386028)
9. St John SuttonM, Rendell M, Dandona P, et al. A comparison of the effects of rosiglitazone and glyburide on cardiovascular function and glycemic control in patients with type 2 diabetes. Diabetes Care 2002; 25: 2058-64
10. Kannel WB, Hjortland M, Castelli WP. Role of diabetes in congestive heart failure: The Framingham Study. Am J Cardiol 1974; 34: 29-34
11. Tang WH. Do thiazolidinediones cause heart failure? A critical review. Cleve Clinic J Med 2006; 73: 390-6
12. Mannucci E, Monami M, Di Bari M, et al. Cardiac safety profile of rosiglitazone: A comprehensive meta-analysis of randomized clinical trials. Int J Cardiol 2009. doi: 10.1016/j.ijcard.2009.01.064
13. Johnson JA,Majumdar SR, Simpson SH, et al. Decreased mortality associated with the use ofmetformin compared with sulfonylurea monotherapy in type 2 diabetes. Diabetes Care 2002; 25: 2244-8 (Pubitemid 41071035)
14. Koro CE, Bowlin SJ, Weiss SR. Antidiabetic therapy and the risk of heart failure in type 2 diabetic patients: An independent effect or confounding by indication. Pharmacoepidemiol Drug Saf 2005; 14: 697-703 (Pubitemid 41489449)
15. Hernandez AV, Walker E, Ioannidis JP, et al. Challenges in meta-analysis of randomized clinical trials for rare harmful cardiovascular events: The case of rosiglitazone. Am Heart J 2008; 156: 23-30
16. Sweeting MJ, Sutton AJ, Lambert PC. What to add to nothing? Use and avoidance of continuity corrections in meta-analysis of sparse data. Stat Med 2004; 23: 1351-75 (Pubitemid 38594143)
17. Bradburn MJ, Deeks JJ, Berlin JA, et al. Much ado about nothing: A comparison of the performance of meta-analytical methods with rare events. Stat Med 2007; 26: 53-77 (Pubitemid 46099417)
18. Hernandez AV, Westerhout CM, Steyerberg EW, et al. Effects of platelet glycoprotein IIb/IIIa receptor blockers in non-ST segment elevation acute coronary syndromes: Benefit and harm in different age subgroups. Heart 2007; 93: 450-5 (Pubitemid 46631509)
19. Jadad AR, Moore RA, Carroll D, et al. Assessing the quality of reports of randomized clinical trials: Is blinding necessary?Control Clin Trials 1996; 17: 1-12 (Pubitemid 26120810)
20. Moher D, Liberati A, Tetzlaff J, et al. Preferred reporting items for systematic reviews and meta-analyses: The PRISMA statement. Ann Intern Med 2009; 151: 264-9
21. Higgins JP, Thompson SG. Quantifying heterogeneity in a meta-analysis. Stat Med 2002; 21: 1539-58 (Pubitemid 34746062)
22. Egger M, Altman DG, Smith GD. Systematic reviews in health-care: Metaanalysis in context. 2nd ed. London: BMJ Books, 2001
23. Yusuf S, Peto R, Lewis J, et al. Beta blockade during and after myocardial infarction: An overview of the randomized trials. Prog Cardiovasc Dis 1985; 27: 335-71 (Pubitemid 15107153)
24. Der Simonian R, Laird N. Meta-analysis in clinical trials. Control Clin Trials 1986; 7: 177-88 (Pubitemid 17189972)
25. van Houwelingen HC, Arends LR, Stijnen T. Advanced methods in metaanalysis: Multivariate approach and meta-regression. Stat Med 2002; 21: 589-624 (Pubitemid 34141379)
26. AgrawalA, SautterMC, JonesNP.Effects of rosiglitazonemaleatewhen added to a sulfonylurea regimen in patients with type 2 diabetes mellitus and mild to moderate renal impairment: A post hoc analysis. Clin Ther 2003; 25: 2754-64 (Pubitemid 37510588)
27. Albertini J-P, McMorn SO, Chen H, et al. Effect of rosiglitazone on factors related to endothelial dysfunction in patients with type 2 diabetes mellitus. Atherosclerosis 2007; 195: E159-66 (Pubitemid 47569985)
28. Barnett AH, Grant PJ, Hitman GA, et al. Rosiglitazone in type 2 diabetes: An evaluation in British Indo-Asian patients. Diabet Med 2003; 20: 387-93 (Pubitemid 36605624)
29. Bhatt DL, Chew DP, Grines C, et al. Peroxisome proliferator-activated receptor g agonists for the prevention of adverse events following percutaneous coronary revascularization: Results of the PPAR Study. Am Heart J 2007; 154: 137-43 (Pubitemid 46920478)
30. Cao Z, Zhou YJ, Zhao YX, et al. Rosiglitazone could improve clinical outcomes after coronary stent implantation in non-diabetic patients with metabolic syndrome. Chin Med J 2006; 119: 1171-5 (Pubitemid 44111163)
31. Dailey GE, Noor MA, Park J-S, et al. Glycemic control with glyburide/ metformin tablets in combination with rosiglitazone in patients with type 2 diabetes: A randomized double-blind trial. Am J Med 2004; 116: 223-9 (Pubitemid 38224229)
32. Dargie HJ,Hildebrandt PR, Riegger GA, et al. Arandomized, placebo-controlled trial assessing the effects of rosiglitazone on echocardiographic function and cardiac status in type 2 diabetic patients with New York Heart Association functional class I or II heart failure. J Am Coll Cardiol 2007; 49: 1696-704 (Pubitemid 46589926)
33. Davidson JA, McMorn SO, Waterhouse BR, et al. A 24 week, multicenter, randomized, double-blind, placebo-controlled, parallel-group study of the efficacy and tolerability of combination therapy with rosiglitazone and sulfonylurea in African American and Hispanic American patients with type 2 diabetes inadequately controlled with sulfonylurea monotherapy. Clin Ther 2007; 29: 1900-14 (Pubitemid 350214459)
34. Fonseca V, Rosenstock J, Patwardhan R, et al. Effect of metformin and rosiglitazone combination therapy in patients with type 2 diabetes mellitus: A randomized controlled trial. JAMA 2000; 283: 1695-702 (Pubitemid 30196209)
35. Gerstein HC, Yusuf S, Bosch J, et al. Effect of rosiglitazone on the frequency of diabetes in patients with impaired glucose tolerance or impaired fasting glucose: A randomised controlled trial. Lancet 2006; 368: 1096-105
36. Gómez-Perez FJ, Fanghänel-Salmón G, Barbosa JA, et al. Efficacy and safety of rosiglitazone plus metformin in Mexicans with type 2 diabetes. Diabetes Metab Res Rev 2002; 18: 127-34 (Pubitemid 34467302)
37. Hedblad B, Zambanini A, Nilsson P, et al. Rosiglitazone and carotid IMT progression rate in a mixed cohort of patients with type 2 diabetes and the insulin resistance syndrome: Main results from the Rosiglitazone Atherosclerosis Study. J Intern Med 2007; 261: 293-305
38. Hollander P, Yu D, Chou HS. Low-dose rosiglitazone in patients with insulinrequiring type 2 diabetes. Arch Intern Med 2007; 167: 1284-90 (Pubitemid 46998500)
39. Lebovitz HE, Dole JF, Patwhardhan R, et al., for the Rosiglitazone Clinical Trials Study Group. Rosiglitazone monotherapy is effective in patients with type 2 diabetes. J Clin Endocrinol Metab 2001; 86: 280-8 (Pubitemid 32109807)
40. Phillips LS, Grunberger G, Miller E, et al. Once- and twice-daily dosing with rosiglitazone improves glycemia control in patients with type 2 diabetes. Diabetes Care 2001; 24: 308-15 (Pubitemid 32119130)
41. Raskin P, Rendell M, Riddle MC, et al. A randomized trial of rosiglitazone therapy in patients with inadequately controlled insulin-treated type 2 diabetes. Diabetes Care 2001; 24: 1226-32 (Pubitemid 33716403)
42. Rosenstock J, Goldstein BJ, Vinik AI, et al. Effect of early addition of rosiglitazone to sulphonylurea therapy in older type 2 diabetes patients (>60 years): The Rosglitazone Early vs SULphonylurea Titration (RESULT) study. Diabetes Obes Metab 2006; 8: 49-57
43. Zhu XX, Pan CY, Li GW, et al. Addition of rosiglitazone to existing sulfonylurea treatment in Chinese patients with type 2 diabetes and exposure to hepatitis B or C. Diabetes Technol Ther 2003; 5: 33-42
44. Aronoff S, Rosenblatt S, Braithwaite S, et al. Pioglitazone hydrochloride monotherapy improves glycemic control in the treatment of patients with type 2 diabetes: A 6-month randomized placebo-controlled dose-response study. Diabetes Care 2000; 23: 1605-11
45. Berhanu P, Perez A, Yu S. Effect of pioglitazone in combination with insulin therapy on glycaemic control, insulin dose requirement and lipid profile in patients with type 2 diabetes previously poorly controlled with combination therapy. Diabetes Obes Metab 2007; 9: 512-20 (Pubitemid 47018515)
46. Einhorn D, Rendell M, Rosenzweig J, et al. Pioglitazone hydrochloride in combination with metformin in the treatment of type 2 diabetes mellitus: A randomized, placebo-controlled study. The Pioglitazone 027 Study Group. Clin Ther 2000; 22: 1395-409 (Pubitemid 32056079)
47. Erdmann E, Charbonnel B, Wilcox RG, et al. Pioglitazone use and heart failure in patients with type 2 diabetes and pre-existing cardiovascular disease: data from the PRO active study (PROactive 08). Diabetes Care 2007; 30: 2773-8 (Pubitemid 350083116)
48. Goldstein BJ, Rosenstock J, Anzalone D, et al. Effect of tesaglitazar, a dual PPARa/g agonist, on glucose and lipid abnormalities in patients with type 2 diabetes: A 12-week dose-ranging trial. Curr Med Res Opin 2006; 22: 2575-90 (Pubitemid 46048373)
49. Herz M, Johns D, Reviriego J, et al. A randomized, double-blind, placebocontrolled, clinical trial of the effects of pioglitazone on glycemic control and dyslipidemia in oral antihyperglycemic medication-naïve patients with type 2 diabetes mellitus. Clin Ther 2003; 25: 1074-95 (Pubitemid 36532579)
50. Kipnes MS, Krosnick A, Rendell MS, et al. Pioglitazone hydrochloride in combination with sulfonylurea therapy improves glycemic control in patients with type 2 diabetes mellitus: A randomized, placebo-controlled study. Am J Med 2001; 111: 10-7 (Pubitemid 32635256)
51. Mattoo V, Eckland D, Widel M, et al. Metabolic effect of pioglitazone in combination with insulin in patients with type 2 diabetes mellitus whose disease is not adequately controlled with insulin therapy: Results of a six-month, randomized, double-blind, prospective, multicenter, parallel-group study. Clin Ther 2005; 27: 554-67 (Pubitemid 40835966)
52. Rosenblatt S, Miskin B, Glazer NB, et al., and the Pioglitazone 026 Study Group. The impact of pioglitazone on glycemic control and atherogenic dyslipidemia in patients with type 2 diabetes mellitus. Coron Artery Dis 2001; 12: 413-23 (Pubitemid 32664824)
53. Rosenstock J, Einhorn D, Hershon K, et al., and the Pioglitazone 014 Study Group. Efficacy and safety of pioglitazone in type 2 diabetes: A randomised, placebo-controlled study in patients receiving stable insulin therapy. Int J Clin Pract 2002; 56: 251-7 (Pubitemid 34625022)
54. Scherbaum WA, Göke B, and the German Pioglitazone Study Group. Metabolic efficacy and safety of once-daily pioglitazone monotherapy in patients with type 2 diabetes: A double-blind, placebo-controlled study. Horm Metab Res 2002; 34: 589-95 (Pubitemid 35370368)
55. Temple R, Ellenberg SS. Placebo-controlled trials and active-control trials in the evaluation of new treatments. Ann Intern Med 2000; 133: 455-63
56. Singh S, Loke YK, Furberg CD. Thiazolidinediones and heart failure: A teleoanalysis. Diabetes Care 2007; 30: 2148-53
57. Mannucci E, Monami M, Lamanna C, et al. Pioglitazone and cardiovascular risk: A comprehensive meta-analysis of randomized clinical trials. Diabetes Obes Metab 2008; 10: 1221-38
58. Richter B, Bandeira-Echtler E, Bergerhoff K, et al. Rosiglitazone for type 2 diabetes mellitus. Cochrane Database of Systematic Reviews 2007; Issue 3: CD006063. doi: 10.1002/14651858.CD006063.pub2 (Pubitemid 351805644)
59. Richter B, Bandeira-Echtler E, Bergerhoff K, et al. Pioglitazone for type 2 diabetes mellitus. Cochrane Database of Systematic Reviews 2007; Issue 4: CD006060. doi: 10.1002/14651858.CD006060.pub2
60. Winkelmayer WC, Setoguchi S, Levin R, et al. Comparison of cardiovascular outcomes in elderly patients with diabetes who initiated rosiglitazone vs pioglitazone therapy. Arch Intern Med 2008; 168: 2368-75
61. Juurlink DN, Gomes T, Lipscombe LL, et al. Adverse cardiovascular events during treatment with pioglitazone and rosiglitazone: Population based cohort study. BMJ 2009; 339: B2942
62. Graham DJ, Ouellet-Hellstrom R, MaCurdy TE, et al. Risk of acute myocardial infarction, stroke, heart failure, and death in elderly Medicare patients treated with rosiglitazone or pioglitazone. JAMA 2010; 304: 411-8
63. Guan Y, Hao C, Cha DR, et al. Thiazolidinediones expand body fluid volume through PPARgamma stimulation of ENaC-mediated renal salt absorption. Nat Med 2005; 11: 861-6 (Pubitemid 41161118)
64. Wertz DA, Chang CL, Sarawate CA, et al. Risk of cardiovascular events and all-cause mortality in patients treated with thiazolidinediones in a managedcare population. Circ Cardiovasc Qual Outcomes 2010; 3: 538-45
65. Rutter MK, Parise H, Benjamin EJ, et al. Impact of glucose intolerance and insulin resistance on cardiac structure and function: Sex-related differences in the Framingham Heart Study. Circulation 2003; 107: 448-54 (Pubitemid 36158048)
66. Hutton JL. Number needed to treat and number needed to harm are not the best way to report and assess the results of randomised clinical trials. Br J Haematol 2009; 146: 27-30
67. McAlister FA. The "number needed to treat" turns 20 - and continues to be used and misused. CMAJ 2008; 179: 549-53
68. Massel D. The number need to harm: Is it too optimistic? Can J Cardiol 2003; 19: 1490-2 (Pubitemid 38139343)
69. Loke YK, Singh S, Furberg CD. Long-term use of thiazolidinediones and fractures in type 2 diabetes: A meta-analysis. CMAJ 2009; 180: 32-9
70. Nathan DM, Buse JB, Davidson MB, et al. Medical management of hyperglycemia in type 2 diabetes: A consensus algorithm for the initiation and adjustment of therapy. A consensus statement of the American Diabetes Association and the European Association for the Study of Diabetes. Diabetes Care 2009; 32: 193-203
71. Home PD, Pocock SJ, Beck-Nielsen H, et al. Rosiglitazone evaluated for cardiovascular outcomes in oral agent combination therapy for type 2 diabetes (RECORD):amulticentre, randomised, open-label trial.Lancet 2009; 373: 2125-35
72. USFDADrug Safety andAvailability. Postmarket drug safety information for patients and providers [online]. Available from URL: Http://www.fda.gov/ Drugs/DrugSafety/PostmarketDrugSafetyInformationforPatientsandProviders/ ucm226976.htm [Accessed 2010 Dec 8]
73. European Medicines Agency press release. European Medicines Agency recommends suspension of Avandia, Avandamet and Avaglim [online]. Available from URL: Http://www.ema.europa.eu/docs/en-GB/document-library/ Press-release/2010/ 09/WC500096996.pdf [Accessed 2010 Dec 8]